Curis Company Profile (NASDAQ:CRIS)

About Curis (NASDAQ:CRIS)

Curis logoCuris, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CRIS
  • CUSIP: 23126910
  • Web:
  • Market Cap: $244.41 million
  • Outstanding Shares: 143,772,000
Average Prices:
  • 50 Day Moving Avg: $2.20
  • 200 Day Moving Avg: $2.73
  • 52 Week Range: $1.47 - $3.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.93 million
  • Price / Sales: 30.82
  • Book Value: $0.15 per share
  • Price / Book: 11.33
  • EBIDTA: ($46,080,000.00)
  • Net Margins: -861.64%
  • Return on Equity: -99.45%
  • Return on Assets: -63.44%
  • Debt-to-Equity Ratio: 0.42%
  • Current Ratio: 4.54%
  • Quick Ratio: 4.54%
  • Average Volume: 581,136 shs.
  • Beta: 1.89
  • Short Ratio: 3.97

Frequently Asked Questions for Curis (NASDAQ:CRIS)

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. The firm earned $2.13 million during the quarter, compared to analyst estimates of $1.98 million. Curis had a negative net margin of 861.64% and a negative return on equity of 99.45%. Curis's revenue was up 23.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) earnings per share. View Curis' Earnings History.

When will Curis make its next earnings announcement?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Curis.

Where is Curis' stock going? Where will Curis' stock price be in 2017?

4 brokers have issued 1 year target prices for Curis' shares. Their forecasts range from $6.00 to $7.00. On average, they expect Curis' share price to reach $6.67 in the next twelve months. View Analyst Ratings for Curis.

What are analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

  • 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (5/10/2017)
  • 2. Cowen and Company analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Who owns Curis stock?

Curis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Eagle Investment Management LLC (16.92%), FMR LLC (10.66%), Vanguard Group Inc. (3.40%), Geode Capital Management LLC (0.65%), Point72 Asset Management L.P. (0.35%) and Perceptive Advisors LLC (0.35%). Company insiders that own Curis stock include Daniel R Passeri, Discovery Technologie Aurigene, James R Mcnab, Kenneth I Kaitin and Martyn D Greenacre. View Institutional Ownership Trends for Curis.

Who sold Curis stock? Who is selling Curis stock?

Curis' stock was sold by a variety of institutional investors in the last quarter, including TFS Capital LLC, Morgan Stanley, JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Ameriprise Financial Inc., ProShare Advisors LLC, KCG Holdings Inc. and Bank of New York Mellon Corp. Company insiders that have sold Curis stock in the last year include James R Mcnab, Kenneth I Kaitin and Martyn D Greenacre. View Insider Buying and Selling for Curis.

Who bought Curis stock? Who is buying Curis stock?

Curis' stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, FMR LLC, Vanguard Group Inc., Highbridge Capital Management LLC, Geode Capital Management LLC, Vident Investment Advisory LLC and Prudential Financial Inc.. View Insider Buying and Selling for Curis.

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Curis stock cost?

One share of Curis stock can currently be purchased for approximately $1.70.

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.67 (292.16% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$6.00LowView Rating Details
10/12/2016Royal Bank of CanadaSet Price TargetBuy$7.00N/AView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00N/AView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$3.00N/AView Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
7/6/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Curis (NASDAQ:CRIS)
Earnings by Quarter for Curis (NASDAQ:CRIS)
Earnings History by Quarter for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 17($0.09)($0.11)$1.98 million$2.13 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.10)($0.08)$1.97 million$2.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.05)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Curis (NASDAQ:CRIS)
2017 EPS Consensus Estimate: ($0.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.07)($0.07)($0.07)
Q3 20171($0.07)($0.07)($0.07)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Curis (NASDAQ:CRIS)
Insider Ownership Percentage: 6.09%
Institutional Ownership Percentage: 49.49%
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2017James R McnabDirectorSell76,276$2.04$155,603.04View SEC Filing  
5/2/2017James R McnabDirectorSell116,708$2.38$277,765.04View SEC Filing  
4/27/2017James R McnabDirectorSell146,694$2.61$382,871.34View SEC Filing  
4/24/2017James R McnabDirectorSell110,322$2.59$285,733.98View SEC Filing  
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.20View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Curis (NASDAQ:CRIS)
Latest Headlines for Curis (NASDAQ:CRIS)
DateHeadline logoCuris Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting - May 25 at 6:04 PM logoETFs with exposure to Curis, Inc. : May 22, 2017 - May 22 at 4:19 PM logoCuris, Inc. (CRIS) Expected to Post Quarterly Sales of $2.06 Million - May 12 at 1:36 PM logoETFs with exposure to Curis, Inc. : May 11, 2017 - May 11 at 5:06 PM logoZacks Investment Research Downgrades Curis, Inc. (CRIS) to Sell - May 10 at 8:56 PM logoZacks: Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS - May 10 at 4:26 PM logoCuris, Inc. :CRIS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 4:28 PM logoCuris, Inc. 52 Weeks Later: The Risk Grows, But The Investment Thesis Remains Promising - May 5 at 9:44 PM logoCuris, Inc. (CRIS) Stock Rating Reaffirmed by Cowen and Company - May 5 at 9:34 PM logoJames R. Mcnab Sells 76,276 Shares of Curis, Inc. (CRIS) Stock - May 5 at 8:37 PM logoCuris, Inc. (CRIS) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - May 4 at 11:10 PM logoEdited Transcript of CRIS earnings conference call or presentation 4-May-17 12:30pm GMT - May 4 at 9:40 PM logoEARNINGS SUMMARY: Details of Curis Inc Q1 Earnings Report - May 4 at 4:37 PM logoCuris Chairman James McNab Jr. To Retire, Martyn Greenacre Named Successor - May 4 at 4:37 PM logoInvestor Network: Curis, Inc. to Host Earnings Call - May 4 at 4:37 PM logoCuris reports 1Q loss - May 4 at 8:19 AM logoCuris Reports First Quarter 2017 Financial Results - May 4 at 7:31 AM logoFavorable Media Coverage Somewhat Unlikely to Affect Curis (CRIS) Share Price - May 3 at 12:46 AM logoCuris, Inc. (CRIS) Director James R. Mcnab Sells 116,708 Shares - May 2 at 9:54 PM logoCuris (CRIS) Receiving Positive Press Coverage, Analysis Finds - April 29 at 6:11 PM logoCuris to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017 - April 28 at 5:27 PM logoJames R. Mcnab Sells 146,694 Shares of Curis, Inc. (CRIS) Stock - April 27 at 9:40 PM logoCuris, Inc. – Value Analysis (NASDAQ:CRIS) : April 25, 2017 - April 27 at 2:11 AM logoCuris, Inc. (CRIS) Expected to Announce Earnings of -$0.09 Per Share - April 27 at 1:14 AM logoZacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2 Million - April 27 at 1:13 AM logoCuris (CRIS) Getting Positive Media Coverage, Study Finds - April 27 at 12:48 AM logoCuris, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 24, 2017 - April 24 at 9:24 AM logoCuris (CRIS) Earns Daily Media Sentiment Score of 0.33 - April 23 at 2:09 PM logoCuris, Inc. (CRIS) Expected to Post Quarterly Sales of $2 Million - April 21 at 2:04 PM logoSomewhat Positive News Coverage Extremely Likely to Affect Curis (CRIS) Stock Price - April 20 at 6:38 PM logoCuris (CRIS) Earns Media Impact Rating of 0.31 - April 17 at 9:38 AM logoCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 7 at 9:12 AM logoCuris, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 6, 2017 - April 7 at 9:12 AM logoCuris (CRIS) to Unveil Pre-Clinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Meeting 4/1-4/5 - March 30 at 4:56 PM logo1:31 pm Curis will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the AACR Meeting on April 3 - March 30 at 4:56 PM logoCuris, Inc. (CRIS) Rating Reiterated by Cowen and Company - March 22 at 1:43 PM logoCuris to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference - March 16 at 5:52 PM logoCuris, Inc. (CRIS) Stock Rating Upgraded by Zacks Investment Research - March 14 at 9:27 PM logoCURIS INC Financials - March 14 at 1:18 PM logoCuris, Inc. (CRIS) Given a $6.00 Price Target at FBR & Co - March 12 at 10:51 PM logoMarkets Rally Late to Close in the Green: Today's Research Reports on Stocks to Watch Curis and Staples - March 10 at 11:48 AM logoEdited Transcript of CRIS earnings conference call or presentation 9-Mar-17 1:30pm GMT - March 9 at 10:07 PM logoEARNINGS SUMMARY: Details of Curis Inc Q4 Earnings Report - March 9 at 5:05 PM logoCuris Enters Into $45 Mln Debt Transaction With HealthCare Royalty - Quick Facts - March 9 at 5:05 PM logoCuris's (CRIS) CEO Ali Fattaey on Q4 2016 Results - Earnings Call Transcript - March 9 at 5:05 PM logoQ4 2016 Curis Inc Earnings Release - Before Market Open - March 9 at 5:05 PM logoCURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 9 at 5:05 PM logoCuris reports 4Q loss - March 9 at 5:05 PM logoCuris Inc Earnings Call scheduled for 8:30 am ET today - March 9 at 5:05 PM logoCuris, Inc. (CRIS) Expected to Earn FY2016 Earnings of ($0.33) Per Share - March 9 at 10:48 AM



Curis (CRIS) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff